Kiromic BioPharma is an artificial intelligence driven, end-to-end Chimeric Antigen Receptor T cell (CAR-T cell) and gene therapy company, developing the multi-indication allogeneic CAR-T cell therapy, that exploits the natural potency of the Gamma Delta T cell to target solid tumors. Co. develops its brand of CAR-T cell product candidates known as ALEXIS. The product candidates are: ALEXIS-ISO-1, an allogenic gamma delta CAR-T cell therapy product candidate targeting Isomesothelin; and ALEXIS-PRO-1, an allogeneic gamma delta chimeric T cell therapy product candidate targeting PD-L1. These are designed to treat cancer by capitalizing on the immune system's ability to destroy cancer cells. The KRBP stock yearly return is shown above.
The yearly return on the KRBP stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2022 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the KRBP annual return calculation with any dividends reinvested as applicable (on ex-dates).
|